Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Non-Current Debt (2023 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Non-Current Debt for 3 consecutive years, with $220.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Debt rose 1.53% year-over-year to $220.3 million, compared with a TTM value of $220.3 million through Dec 2025, up 1.53%, and an annual FY2025 reading of $220.3 million, up 1.53% over the prior year.
  • Non-Current Debt was $220.3 million for Q4 2025 at Xeris Biopharma Holdings, roughly flat from $219.5 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $220.3 million in Q4 2025 and bottomed at $190.9 million in Q4 2023.
  • Average Non-Current Debt over 3 years is $214.0 million, with a median of $218.2 million recorded in 2025.
  • The sharpest move saw Non-Current Debt grew 13.66% in 2024, then rose 1.53% in 2025.
  • Year by year, Non-Current Debt stood at $190.9 million in 2023, then grew by 13.66% to $217.0 million in 2024, then increased by 1.53% to $220.3 million in 2025.
  • Business Quant data shows Non-Current Debt for XERS at $220.3 million in Q4 2025, $219.5 million in Q3 2025, and $218.6 million in Q2 2025.